Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate, House Appropriations Conference Looms; User Fee Funds Lacking

This article was originally published in The Gray Sheet

Executive Summary

CDRH is unlikely to receive $15 mil. in additional funds in FY 2003 for user fees, making the task of obtaining the $45 mil. necessary to sustain the fledgling program beyond 2005 all the more difficult

You may also be interested in...



Industry, Rep. Buyer Urge Appropriators To Meet User Fee Funding Goals

Congress may reexamine the amount of funds allocated to the device user fee program in the omnibus FY 2003 spending bill, following the Feb. 3 release of President Bush's FY 2004 budget request, which designates only $1 mil. for premarket review activities at CDRH

Industry, Rep. Buyer Urge Appropriators To Meet User Fee Funding Goals

Congress may reexamine the amount of funds allocated to the device user fee program in the omnibus FY 2003 spending bill, following the Feb. 3 release of President Bush's FY 2004 budget request, which designates only $1 mil. for premarket review activities at CDRH

Congress To OMB: Adequate Funds Needed For User Fee Program In FY 2004

Congressional health panel chairmen are strongly urging White House Office of Management & Budget Director Mitch Daniels to set aside $15 mil. for medical device user fees in the administration's FY 2004 budget request

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel